Table 1.
Comparison of ERBB receptor and ligand expression in “IL‐13 high” and “IL‐17 high” asthma clusters relative to health in the U‐BIOPRED cohort
| n | “IL‐13 low/IL‐17 low” | “IL‐17 high” | “IL‐13 high” | |||
|---|---|---|---|---|---|---|
| 53 | 22 | 9 | ||||
| Log2 fold change | P | Log2 fold change | P | Log2 fold change | P | |
| EGFR | −0.017 | .1761 | −0.079 | .0001 | −0.097 | .0011 |
| ERBB2 | −0.007 | .2059 | −0.031 | .0006 | −0.026 | .0157 |
| ERBB3 | 0.034 | .0953 | 0.083 | .0043 | 0.098 | .0019 |
| ERBB4 | 0.096 | .0008 | −0.090 | .0501 | −0.059 | .2681 |
| EGF | 0.007 | .6470 | 0.076 | .0003 | 0.049 | .0621 |
| TGFA | 0.006 | .7253 | −0.008 | .7356 | −0.027 | .4088 |
| HBEGF | 0.015 | .2612 | 0.027 | .1056 | 0.081 | .0002 |
| BTC | −0.027 | .1971 | −0.124 | .0000 | −0.071 | .0359 |
| AREG | 0.040 | .3029 | 0.225 | .0011 | 0.043 | .5383 |
| EREG | 0.022 | .5274 | 0.344 | .0019 | 0.105 | .0863 |
Numbers are log2 fold change relative to expression in healthy participants; significant changes are highlighted in bold. The definition of “IL‐13 high” and “IL‐17 high” was based on that used in.18